Here’s the press release they sent out this morning
FDA to Enforce Against Cannabis Health Claims?
Commissioner Scott Gottlieb of the U.S. Food and Drug Administration (FDA) thinks it’s “high time to start looking at rules around [cannabis].” Given that twenty-nine states and Washington, D.C. have already legalized medical marijuana, Gottlieb’s concern is a little late, but it signals change is afoot.
From a branding and advertising perspective, what might this mean? For now, that depends on a company’s labeling and advertising. The FDA has extensive power to regulate food and drugs, and it determines whether something is a food or drug by looking to product labels and advertisements. If a label makes health claims, signaling to the FDA that the substance is a drug, the FDA will view it with great scrutiny.
For some guidance, consider the FDA warning letters sent in 2015 and 2016 admonishing companies about cannabidiol (CBD) claims. It publicly warned everyone that the “claims on your websites establish that these products are drugs under [the Federal Food, Drug, and Cosmetic Act] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.” The FDA took issue with a wide variety of health claims, including:
Are tetrahydrocannabinol (THC) claims next? The FDA has avoided regulating products infused with THC, but this position could shift. For Gottlieb, “it’s a much broader question about where our responsibility is to step into this [with] people who are developing products [and] making claims that marijuana has antitumor effects in the setting of cancer.”
If you’re unsure whether your cannabis products are labeled with appropriate claims, contact us. We offer complete review services for packaging and marketing materials. We provide tailored branding advice for all cannabis products.